{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:56:38Z","timestamp":1794110198466,"version":"4.8.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.medj.2023.12.004","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T10:37:53Z","timestamp":1704364673000},"page":"42-61.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19"],"prefix":"10.1016","volume":"5","author":[{"given":"Long","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namir","family":"Shaabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Argent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Kushnareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Stegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengdian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Kotoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kerwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila","family":"Chumakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Teijaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Royal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Brunswick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2023.12.004_bib1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.12.004_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2023.04.401","article-title":"Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from 12 July 2021 to 6 June 2022: a prospective cohort study","volume":"133","author":"Huiberts","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.medj.2023.12.004_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.medj.2023.12.004_bib4","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1021\/acs.jcim.1c00449","article-title":"Dynamic Profiling of beta-Coronavirus 3CL M(pro) Protease Ligand-Binding Sites","volume":"61","author":"Cho","year":"2021","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.medj.2023.12.004_bib5","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.medj.2023.12.004_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193982","article-title":"Two key cathepsins, TgCPB and TgCPL, are targeted by the vinyl sulfone inhibitor K11777 in in\u00a0vitro and in\u00a0vivo models of toxoplasmosis","volume":"13","author":"Chaparro","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.medj.2023.12.004_bib7","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2023.12.004_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","article-title":"Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir","volume":"9","author":"Hu","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.medj.2023.12.004_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add7197","article-title":"Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system","volume":"8","author":"Zhou","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.medj.2023.12.004_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02815-22","article-title":"The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In\u00a0Vitro and Confer Resistance To Nirmatrelvir","volume":"14","author":"Jochmans","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.medj.2023.12.004_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107587","article-title":"Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients","volume":"213","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.medj.2023.12.004_bib12","article-title":"The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry","author":"Peacock","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.medj.2023.12.004_bib13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","article-title":"SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway","volume":"7","author":"Willett","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.medj.2023.12.004_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.medj.2023.12.004_bib15","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021107821","article-title":"TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells","volume":"40","author":"Koch","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.medj.2023.12.004_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.12.004_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/acschembio.0c00875","article-title":"A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells","volume":"16","author":"Mellott","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.medj.2023.12.004_bib18","article-title":"MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L","volume":"17","author":"Ma","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.medj.2023.12.004_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.medj.2023.12.004_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.12.004_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.12.004_bib50","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.medj.2023.12.004_bib22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.medj.2023.12.004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.medj.2023.12.004_bib24","series-title":"Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid","author":"FDA","year":"2023"},{"key":"10.1016\/j.medj.2023.12.004_bib25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","volume":"613","author":"Iketani","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.12.004_bib26","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1021\/acs.jcim.3c00344","article-title":"Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease","volume":"63","author":"Clayton","year":"2023","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.medj.2023.12.004_bib27","doi-asserted-by":"crossref","first-page":"eabq7360","DOI":"10.1126\/scitranslmed.abq7360","article-title":"SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376","volume":"15","author":"Heilmann","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.medj.2023.12.004_bib28","article-title":"Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape Strategies","author":"Lan","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.medj.2023.12.004_bib29","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.medj.2023.12.004_bib30","article-title":"COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022","author":"Wang","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.medj.2023.12.004_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciad102","article-title":"The COVID-19 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated with Nirmatrelvir Plus Ritonavir Versus Untreated Controls","volume":"77","author":"Pandit","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2023.12.004_bib32","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/cid\/ciac512","article-title":"Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)","volume":"76","author":"Boucau","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2023.12.004_bib33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.7326\/M22-2381","article-title":"Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection","volume":"176","author":"Deo","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.medj.2023.12.004_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciad102","article-title":"The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls","volume":"77","author":"Pandit","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2023.12.004_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105430","article-title":"Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice","volume":"208","author":"Jeong","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.medj.2023.12.004_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03331-22","article-title":"Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2","volume":"10","author":"Wagoner","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.medj.2023.12.004_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acscentsci.1c00910","article-title":"Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay","volume":"8","author":"Cao","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.medj.2023.12.004_bib38","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1021\/acsinfecdis.0c00761","article-title":"Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses","volume":"7","author":"Hu","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.medj.2023.12.004_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111779","article-title":"Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro\/3CLpro) and Human Cathepsin-L","volume":"22","author":"Costanzi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.medj.2023.12.004_bib40","doi-asserted-by":"crossref","first-page":"21035","DOI":"10.1021\/jacs.2c04626","article-title":"Dual Inhibitors of Main Protease (M(Pro)) and Cathepsin L as Potent Antivirals against SARS-CoV2","volume":"144","author":"Mondal","year":"2022","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.medj.2023.12.004_bib41","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.1038\/s41598-021-89013-w","article-title":"Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model","volume":"11","author":"C\u00e1ceres","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.medj.2023.12.004_bib42","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101555118","article-title":"Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection","volume":"118","author":"Dampalla","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.medj.2023.12.004_bib43","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.medj.2023.12.004_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8778","article-title":"Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors","volume":"9","author":"Moghadasi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.medj.2023.12.004_bib45","article-title":"Nirmatrelvir resistance - de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure - a case report","volume":"45","author":"Zuckerman","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.medj.2023.12.004_bib46","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd2092","article-title":"Targeting proteases: successes, failures and future prospects","volume":"5","author":"Turk","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2023.12.004_bib47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrd3053","article-title":"Emerging principles in protease-based drug discovery","volume":"9","author":"Drag","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2023.12.004_bib48","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.medj.2023.12.004_bib49","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00632-22","article-title":"Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults","volume":"66","author":"Shimizu","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.medj.2023.12.004_bib51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1107\/S0907444910048675","article-title":"iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM","volume":"67","author":"Battye","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib52","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib56","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib57","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1107\/S0907444912001308","article-title":"Towards automated crystallographic structure refinement with phenix.refine","volume":"68","author":"Afonine","year":"2012","journal-title":"Acta\u00a0Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.medj.2023.12.004_bib59","first-page":"705","article-title":"Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants","volume":"3","author":"Duty","year":"2022","journal-title":"M\u00e9d."}],"updated-by":[{"DOI":"10.1016\/j.medj.2024.01.013","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000}}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023004026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634023004026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:58:04Z","timestamp":1778921884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634023004026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2666634023004026"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2023.12.004","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}